Lithium

Lithium

SCHEMBL7189019

CCC(C)Oc1ccc(PC(=O)c2c(OC)cccc2OC)c(OC(C)CC)c1.[Li]

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.38
HDAC1 Q13547 3/20 0.38
HDAC2 Q92769 3/20 0.38
HDAC8 Q9BY41 2/20 0.38
ACACB O00763 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MTNR1A P48039 7/20 0.36
MTNR1B P49286 7/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
CA14 Q9ULX7 1/20 0.36
TSHR P16473 1/20 0.36
TAS1R3 Q7RTX0 1/20 0.34
TAS1R1 Q7RTX1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7189006 0.98 MAPT (0.38) MAPTHDAC1HDAC2HDAC8ACACB
Lithium SCHEMBL7183495 0.93 HDAC1 (0.36) MAPTHDAC1HDAC2HDAC8ACACB
Lithium SCHEMBL7182454 0.92 KMT2A (0.41) HDAC1HDAC2HDAC8ACACBSMN1; SMN2
SCHEMBL7183488 0.91 HDAC1 (0.36) MAPTHDAC1HDAC2HDAC8ACACB
SCHEMBL7182448 0.89 KMT2A (0.41) HDAC1HDAC2HDAC8ACACBSMN1; SMN2
SCHEMBL7180661 0.87 HDAC1 (0.37) MAPTHDAC1HDAC2HDAC8ACACB
Lithium SCHEMBL7182005 0.87 DHODH (0.35) MAPTHDAC1HDAC2HDAC8ACACB
Lithium SCHEMBL7189334 0.87 ACACB (0.34) MAPTHDAC1HDAC2HDAC8ACACB
Lithium SCHEMBL7188428 0.85 BRPF1 (0.41) MAPTSMN1; SMN2CA12CA1CA2
SCHEMBL7186959 0.85 HDAC1 (0.38) MAPTHDAC1HDAC2HDAC8ACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MAPT 4870/4885HDAC1 1556/4885HDAC2 2156/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MAPT 4859/4885HDAC1 1870/4885HDAC2 1993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.